Related references
Note: Only part of the references are listed.Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (ARROW): interim analysis results of a randomised, phase 3 study
Philippe Moreau et al.
LANCET ONCOLOGY (2018)
Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis
Chintan Shah et al.
LEUKEMIA & LYMPHOMA (2018)
Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials
Ajai Chari et al.
BLOOD ADVANCES (2018)
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2017)
The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy
Kyriaki Tzogani et al.
ONCOLOGIST (2017)
Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma
Tania Jain et al.
BLOOD CANCER JOURNAL (2017)
Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): An open-label, phase 1b study.
Andrzej J. Jakubowiak et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Cardiac and renal complications of carfilzomib in patients with multiple myeloma
Meletios A. Dimopoulos et al.
BLOOD ADVANCES (2017)
A practical review on carfilzomib in multiple myeloma
Eli Muchtar et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
Fatal pulmonary toxicity due to carfilzomib (Kyprolis™)
Abdel Rahman Lataifeh et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2016)
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
A. Keith Stewart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma
Thomas M. Herndon et al.
CLINICAL CANCER RESEARCH (2013)
Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature
Andreas A. Argyriou et al.
BLOOD (2008)
Criterion validity of medicare chemotherapy claims in cancer and leukemia group B breast and lung cancer trial participants
EB Lamont et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Share Paper
